Hosted on MSN23h
Takeda broadens its deal with BridGene for up to $770mBridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback